Intranasal esketamine in combination with oral antidepressants demonstrated significant reduction of depressive symptoms and improved overall severity of depressive illness and health-related quality of life and functioning.
Investigators examined the long-term efficacy of deutetrabenazine measured by Abnormal Involuntary Movement Scale, Clinical Global Impressions Scale, and Patients’ Global Impression of Change Scale in real-word clinical practice settings.
Investigators pooled data from 2 phase 3 placebo-controlled studies to evaluate the safety and efficacy of lofexidine for opioid withdrawal symptoms.
In pediatric patients with ADHD, treatment with dasotraline 4 mg/day was effective in treating a range of ADHD-related symptoms and behaviors.
The phase 3 study assessed the antipsychotic efficacy and safety of ALKS 3831 in patients with acute exacerbations of schizophrenia.
Adjunctive raloxifene may reduce negative symptom scores in women with schizophrenia or schizoaffective disorder.
Investigators analyzed the differences in hospitalization outcomes, comorbidities, and utilization of procedures in patients with PD vs patients with PD and MDD.
Bupropion had a greater effect on reducing impulsivity and attention symptoms than escitalopram.
Younger patients treated with antipsychotics after experiencing a first episode of psychosis are at an increased risk for metabolic syndrome and cardiovascular disease.
